Persons with schizophrenia are excluded from psychedelic-assisted therapy due to concerns about the risk of triggering or worsening psychosis. However, there is limited meta-analytic data on the risk of psychedelic-induced psychosis in individuals with pre-existing psychotic disorders. We conducted a systematic review, meta-analysis, and overview of reviews to assess the incidence of...
Promising clinical evidence suggests that psychedelic compounds, like lysergic acid diethylamide (LSD), have therapeutic value for treatment of psychiatric disorders. However, they often produce hallucinations and dissociative states, likely mediated by the serotonin (5-HT) receptor 5-HT2A, raising challenges regarding therapeutic scalability. Given the reported antipsychotic effects of...
Olfactory dysfunction (OD) has become increasingly prevalent since the COVID-19 pandemic, yet effective treatments remain limited. In recent years, anecdotal reports have emerged on the potential benefits of serotonergic psychedelics (lysergic acid diethylamide [LSD], psilocybin, etc.) in improving OD. To date, only one case series in the medical literature has documented this phenomenon. This...
Preliminary evidence suggests that psychedelic-assisted therapy-the enhancement of psychotherapy with psychedelics such as 3,4-methylenedioxymethamphet-amine (MDMA) and psilocybin-may be efficacious for depression, posttraumatic stress disorder, substance use disorders, and other conditions. Therapeutic psychedelic research is advancing steadily, with psilocybin, MDMA, and lysergic acid...
Psychedelic-assisted therapy (PAT) is an emerging treatment approach that often combines pharmacotherapeutic dosing sessions with more traditional psychotherapy. Despite limited formal regulatory approval, treatment seekers can currently access PAT through a variety of avenues, including ketamine treatment centers and “supported adult use” psilocybin centers in the U.S., drug tourism,...
ABSTRACT The serotonergic psychedelics psilocybin, LSD and DMT hold great promise for the development of new treatments for psychiatric conditions such as major depressive disorder, addiction and end‐of‐life anxiety. Previous studies in both animals and humans have confirmed the effects of these drugs on neuronal activity and plasticity. However, the understanding of the mechanisms of action of...
Hallucinogenic substances such as psilocybin, LSD or ecstasy are now the subject of several hundred clinical trials around the world to test their ability to restore our mental health. Psilocybin (active ingredient in hallucinogenic mushrooms), LSD (derived from compounds from ergot), dimethyltryptamine (or DMT, part of the composition of ayahuasca), mescaline (derived from peyote), but also...
February 26, 2025Stanisław Adamczyk, Małgorzata Paczyńska, Anastasia Ruban et al.1 citation
preprint
Psychedelic substances have the potential to induce profound alterations in cognition, emotionality, and sensory perception. The quality and intensity of these subjective effects exhibit high intra- and inter-individual variability, which can potentially be accounted for by the variability in contexts in which psychedelics are used. Therefore, the aim of the present cross-sectional study was to...
Medical ScienceFebruary 25, 2025Jakub Pudźwa, Kamil Gibczyński, Karol Leśniewski et al.
Objective: The purpose of the following review was to summarize the recent studies on proposed mechanisms of action of psychedelic drugs (psilocybin, MDMA, LSD), their therapeutic potential in mental disorders (depression, PTSD, addictions), and the evaluation of their safety. This review also discusses the barriers to the clinical implementation of these agents. Methodology: The paper combines...
Molecular dynamics (MD) simulations have become an essential tool for studying the dynamics of biological systems and exploring protein-ligand interactions. OpenMM is a modern, open-source software toolkit designed for MD simulations. Until now, it has lacked a module dedicated to building receptor-ligand systems, which is highly useful for investigating protein-ligand interactions for drug...